Hiroyuki Taniguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hiroyuki Taniguchi has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Arata Azuma
Mihara General Hospital, Saitama, Japan
6 shared publications - Yasuhiro Kondoh
Department of Respiratory Medicine and Allergology, Aichi Medical University, 1-1 Yazako Karimata, Nagakute, Aichi, 480-1195, Japan; Department of Respiratory Medicine and Allergy, Tosei General Hospital, 160, Nishi-oiwake-cho, Seto, Aichi, 489-8642, Japan
5 shared publications - Moritaka Suga
Center for Preventive Medicine, Saiseikai Kumamoto Hospital, 5-3-1, Tikami, Minami-ku, Kumamoto 861-4193, Japan
4 shared publications - Hiroki Takahashi
Third Department of Internal Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan
3 shared publications - Koichiro Nakata
Department of Respiratory Medicine, Nakata Clinic, 2-2-1, Naikoucho, Chiyodaku, Tokyo 100-0011, Japan
3 shared publications - Takashi Ogura
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan
3 shared publications
Latest Publications
- 11 July 2016
- Published by Wiley in Respirology
- Vol. 21 (8) , 1425-1430
Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
Background and objective: In the two‐replicate randomized Phase III INPULSIS® trials in patients with idiopathic pulmonary fibrosis (IPF), nintedanib 150 mg bd significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo. The key secondary endpoints were time to first investigator‐reported acute exacerbation and change from baseline in St George's Respiratory Questionnaire total score, both over 52 weeks. Here, we assessed the effect of nintedanib in Asian patients.Methods: Pre‐specified subgroup analyses of the effect of nintedanib on the primary and key secondary endpoints in Asian versus White patients were undertaken based on pooled data from the two INPULSIS® trials. Safety data were analyzed descriptively.Results: Of the treated patients, 322 were Asian (nintedanib n = 194; placebo n = 128) and 608 were White (nintedanib n = 360; placebo n = 248). In Asian patients, the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 94.1 mL/year (95% CI: 33.7, 154.6). The treatment effect of nintedanib on the annual rate of decline in FVC in Asian and White patients was similar (treatment‐by‐subgroup interaction P = 0.72) and consistent with the overall population. No significant treatment‐by‐subgroup interaction was observed for the key secondary endpoints between Asian and White patients. In Asian patients, the most common adverse event in the nintedanib group was diarrhoea (56.2% of patients vs 15.6% for placebo).Conclusion: In pre‐specified subgroup analyses of Asian versus White patients with IPF in the INPULSIS® trials, race did not influence the effect of nintedanib on disease progression.
- 11 July 2016
- Published by Wiley in Respirology
- Vol. 21 (8) , 1425-1430
Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis
Background and objective: In the two‐replicate randomized Phase III INPULSIS® trials in patients with idiopathic pulmonary fibrosis (IPF), nintedanib 150 mg bd significantly reduced the annual rate of decline in forced vital capacity (FVC) compared with placebo. The key secondary endpoints were time to first investigator‐reported acute exacerbation and change from baseline in St George's Respiratory Questionnaire total score, both over 52 weeks. Here, we assessed the effect of nintedanib in Asian patients.Methods: Pre‐specified subgroup analyses of the effect of nintedanib on the primary and key secondary endpoints in Asian versus White patients were undertaken based on pooled data from the two INPULSIS® trials. Safety data were analyzed descriptively.Results: Of the treated patients, 322 were Asian (nintedanib n = 194; placebo n = 128) and 608 were White (nintedanib n = 360; placebo n = 248). In Asian patients, the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 94.1 mL/year (95% CI: 33.7, 154.6). The treatment effect of nintedanib on the annual rate of decline in FVC in Asian and White patients was similar (treatment‐by‐subgroup interaction P = 0.72) and consistent with the overall population. No significant treatment‐by‐subgroup interaction was observed for the key secondary endpoints between Asian and White patients. In Asian patients, the most common adverse event in the nintedanib group was diarrhoea (56.2% of patients vs 15.6% for placebo).Conclusion: In pre‐specified subgroup analyses of Asian versus White patients with IPF in the INPULSIS® trials, race did not influence the effect of nintedanib on disease progression.
- 30 March 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (4) , 272-279
Pulmonary alveolar proteinosis-like change: A fairly common reaction associated with the severity of idiopathic pulmonary fibrosis
- 30 March 2016
- Published by Elsevier in Respiratory Investigation
- Vol. 54 (4) , 272-279
Pulmonary alveolar proteinosis-like change: A fairly common reaction associated with the severity of idiopathic pulmonary fibrosis
- Open Access
- 1 January 2016
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 19, 31-33
Acute respiratory distress syndrome due to severe pulmonary tuberculosis treated with extracorporeal membrane oxygenation: A case report and review of the literature
- 1 January 2016
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 19, 31-33
Open AccessAcute respiratory distress syndrome due to severe pulmonary tuberculosis treated with extracorporeal membrane oxygenation: A case report and review of the literature
- 21 October 2015
- Published by Elsevier in Respiratory Investigation
- Vol. 53 (6) , 279-287
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan
- 21 October 2015
- Published by Elsevier in Respiratory Investigation
- Vol. 53 (6) , 279-287
Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan
- 1 September 2015
- Published by Elsevier in Respiratory Investigation
- Vol. 53 (5) , 232-241
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis
- 1 September 2015
- Published by Elsevier in Respiratory Investigation
- Vol. 53 (5) , 232-241
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis
- 10 December 2014
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 45 (5) , 1382-1392
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
A randomised, double-blind, phase II, dose escalation trial was conducted to assess the safety, tolerability and pharmacokinetics of the tyrosine kinase inhibitor nintedanib, alone and when added to ongoing pirfenidone therapy, in Japanese patients with idiopathic pulmonary fibrosis.50 Japanese patients were randomised to receive nintedanib or placebo in one of three cohorts (nintedanib 50 mg twice daily or 100 mg twice daily for 14 days, or 150 mg twice daily for 28 days). Patients receiving pirfenidone at inclusion were stratified to every nintedanib dose group and placebo.Adverse events were reported in nine out of 17 patients receiving nintedanib alone and 10 out of 21 patients receiving nintedanib added to pirfenidone. All adverse events were mild or moderate in intensity. Gastrointestinal disorders were the most common adverse event. Maximum plasma concentration and area under the curve at steady state for nintedanib and its metabolites tended to be lower when nintedanib was added to pirfenidone. Nintedanib had no effect on the pharmacokinetics of pirfenidone.In conclusion, further study is needed to evaluate the safety and tolerability profile of nintedanib when added to pirfenidone in patients with idiopathic pulmonary fibrosis. There was a trend toward lower exposure of nintedanib when it was added to pirfenidone.
- 10 December 2014
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 45 (5) , 1382-1392
Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
A randomised, double-blind, phase II, dose escalation trial was conducted to assess the safety, tolerability and pharmacokinetics of the tyrosine kinase inhibitor nintedanib, alone and when added to ongoing pirfenidone therapy, in Japanese patients with idiopathic pulmonary fibrosis.50 Japanese patients were randomised to receive nintedanib or placebo in one of three cohorts (nintedanib 50 mg twice daily or 100 mg twice daily for 14 days, or 150 mg twice daily for 28 days). Patients receiving pirfenidone at inclusion were stratified to every nintedanib dose group and placebo.Adverse events were reported in nine out of 17 patients receiving nintedanib alone and 10 out of 21 patients receiving nintedanib added to pirfenidone. All adverse events were mild or moderate in intensity. Gastrointestinal disorders were the most common adverse event. Maximum plasma concentration and area under the curve at steady state for nintedanib and its metabolites tended to be lower when nintedanib was added to pirfenidone. Nintedanib had no effect on the pharmacokinetics of pirfenidone.In conclusion, further study is needed to evaluate the safety and tolerability profile of nintedanib when added to pirfenidone in patients with idiopathic pulmonary fibrosis. There was a trend toward lower exposure of nintedanib when it was added to pirfenidone.
- Open Access
- 1 December 2011
- Published by Springer Nature in Respiratory Research
- Vol. 12 (1) , 93
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increasing the progression-free survival (PFS) time by pirfenidone. Recently, marginal decline in forced VC (FVC) has been reported to be associated with poor outcome in IPF. We sought to evaluate the efficacy of pirfenidone from the aspects of 5% change in VC.
- 1 December 2011
- Published by Springer Nature in Respiratory Research
- Vol. 12 (1) , 93
Open AccessThe clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial
Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increasing the progression-free survival (PFS) time by pirfenidone. Recently, marginal decline in forced VC (FVC) has been reported to be associated with poor outcome in IPF. We sought to evaluate the efficacy of pirfenidone from the aspects of 5% change in VC.
- Open Access
- 1 December 2011
- Published by Springer Nature in Respiratory Research
- Vol. 12 (1) , 143
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we analyzed in an exploratory manner the data from the phase III trial.
- 1 December 2011
- Published by Springer Nature in Respiratory Research
- Vol. 12 (1) , 143
Open AccessExploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment
A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we analyzed in an exploratory manner the data from the phase III trial.